Curr Cardiol Rep. 2025 Nov 27;27(1):168. doi: 10.1007/s11886-025-02328-2.
ABSTRACT
PURPOSE OF THE REVIEW: To describe recent advances in knowledge of familial hypercholesterolemia (FH).
RECENT FINDINGS: There has been a significant advance in understanding the natural history, risk stratification, and therapy of FH. Heterozygous FH affects approximately 1 in every 310 individuals worldwide and is associated with an increased risk of premature atherosclerotic cardiovascular disease (ASCVD). Early diagnosis is crucial and relies on clinical criteria and/or genetic testing. Timely initiation of treatment in childhood is imperative, as cumulative exposure to elevated LDL-cholesterol is directly correlated with the onset and progression of ASCVD. Several ASCVD risk prediction models have been developed specifically for adults with FH. Coronary artery calcium scoring is a valuable adjunct to cardiovascular risk stratification in this population. Pharmacological management of FH typically involves statins and ezetimibe, as well as PCSK9 inhibitors. In the elderly, therapeutic strategies must account for age-related factors, such as frailty and comorbidities.
PMID:41307594 | DOI:10.1007/s11886-025-02328-2